Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
2019-004015-31Phase 2Terminated
- Sponsor
- WPD Pharmaceuticals
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berubicin in glioblastoma (GBM), sponsored by WPD Pharmaceuticals. Primary endpoint: Objective Response Rate (ORR) within 6 months. Started May 2021; status: terminated.
02
Drugs
berubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2019-004015-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004015-31.